News | May 16, 2025
Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Standalone profit from operations for the quarter were Rs. 162 crores
EBITDA before special items decreases to €4.08 billion (7.4%)
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Scores highest PAT of Rs. 118 crore in FY25
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
